ArticleJournal of diabetes investigation2026
A study of changes in insulin requirements related to the menstrual cycle in Japanese women with type 1 diabetes using the advanced hybrid closed-loop system.
Article in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
AIMS/
introductionIn type 1 diabetes (T1D), insulin requirements and glycemic control may vary across the menstrual cycle. We examined phase-related differences in insulin requirements, glycemic metrics, and recorded carbohydrate amounts in women using an advanced hybrid closed-loop (AHCL) system and their associations with menstrual symptoms and premenstrual dysphoric disorder (PMDD) screening status. MATERIALS AND
methodsFifteen premenopausal women with T1D using the MiniMed 780G without hormonal therapy were analyzed. Cycles with ≥2 eligible days (SmartGuard ≥70%) in both early follicular (d1-7) and late-luteal (d-7 to -1) phases were included. Phase differences were assessed using linear mixed-effects models. Associations between phase-related changes and menstrual symptom scores and PMDD screening status were evaluated using Spearman correlation and the Mann-Whitney U test, respectively.
resultsEighty cycles were analyzed. Compared with the early follicular phase, the late-luteal phase showed a higher total daily insulin dose (49.2 ± 3.7 vs 45.1 ± 3.7 U/day), basal insulin dose, total bolus insulin, and recorded carbohydrate amount (197.9 ± 18.2 vs 186.1 ± 18.2 g/day), with lower Time in Range (70.0 ± 3.2% vs 72.9 ± 3.2%) and higher Time above Range (TAR). Most phase-related differences persisted after adjustment for recorded carbohydrate amount. No clear associations between menstrual symptom scores or PMDD screening status and phase-related changes were detected.
conclusionDuring AHCL therapy, insulin requirements increased and glycemic control modestly worsened in the late-luteal phase. No clear associations between phase-related metabolic changes and menstrual symptom scores or PMDD screening status were detected in this small cohort.
Indexed as
Identifiers
42847474What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.